In:
The Journal of Immunology, The American Association of Immunologists, Vol. 204, No. 1_Supplement ( 2020-05-01), p. 243.16-243.16
Abstract:
Ovarian cancer is a highly metastatic and the most lethal malignancy of the female reproductive tract. In high grade serous ovarian carcinoma, the presence of tumor infiltrating lymphocytes suggests that this disease can be treated using an immunotherapeutic approach. However, determining candidates who will benefit from immunotherapies such as immune checkpoint inhibitor remains a crucial hurdle. Since immune checkpoint inhibitors work by reactivating an already existing anti-tumor response, a knowledge of the immune cell types within the tumor is required to predict the efficacy of this therapy. The objective of this study was to determine the cellular composition of metastatic ovarian cancer samples using single cell RNA sequencing. Hierarchical clustering of 6 patient samples revealed 2 main groups: a high T cell (2 samples) and 2) a high monocyte signature group (4 samples) suggesting differences in immune response. To assess the immune response in these patient samples, we performed an unsupervised clustering of the T cell population in the two groups. The T cell population clustered into 4 and 3 subpopulations in the high T cell and high monocyte group respectively. A granulysin expressing population was unique to the High T cell group. Interestingly, although both groups had tissue-resident memory CD8+T (CD8+Trm) cells, only the CD8+Trm cells in the high T cell group expressed TOX, a recently described transcription factor. TOX is expressed by exhausted CD8+ T cells that are reactivated in response to PD-L1 immunotherapy. In conclusion, our data reveals a subset of patients that may benefit from novel therapy.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.204.Supp.243.16
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2020
detail.hit.zdb_id:
1475085-5
Permalink